| Menorrhagia

Mirena vs Myfembree

Side-by-side clinical, coverage, and cost comparison for menorrhagia.

Deep comparison between: Mirena vs Myfembree with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsMyfembree has a higher rate of injection site reactions vs Mirena based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Myfembree but not Mirena, including UnitedHealthcare

Category

Mirena

Myfembree

At A Glance

RouteIntrauterine (IUS)

FrequencyContinuous release

ClassProgestin IUS

RouteOral

FrequencyDaily

ClassGnRH receptor antagonist

Indications

Menorrhagia

Uterine Fibroids
Menorrhagia
Endometriosis

Dosing

Contraception Insert 52 mg LNG intrauterine system by a trained healthcare provider using aseptic technique; releases approximately 21 mcg/day initially, declining to approximately 7 mcg/day by year 8; replace by the end of the eighth year.

Menorrhagia Insert 52 mg LNG intrauterine system by a trained healthcare provider using aseptic technique; replace by the end of the fifth year if continued treatment is needed.

Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.

Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.

Contraindications

Pregnancy or suspected pregnancy
Intended use as post-coital (emergency) contraception
Congenital or acquired uterine anomaly, including fibroids, distorting the uterine cavity
Acute pelvic inflammatory disease (PID) or history of PID without a subsequent intrauterine pregnancy
Postpartum endometritis or infected abortion within the past 3 months
Known or suspected uterine or cervical malignancy
Known or suspected breast cancer or other progestin-sensitive cancer, current or past
Uterine bleeding of unknown etiology
Untreated acute cervicitis or vaginitis, including bacterial vaginosis, until infection is controlled
Acute liver disease or liver tumor (benign or malignant)
Conditions associated with increased susceptibility to pelvic infections
Previously inserted IUD that has not been removed
Hypersensitivity to any component of Mirena

High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
Pregnancy
Known osteoporosis
Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
Known hepatic impairment or disease
Undiagnosed abnormal uterine bleeding
Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components

Drug Interactions

475View drug interactions

3337View drug interactions

Adverse Reactions

Most common (>=10%) Alterations of menstrual bleeding patterns (unscheduled uterine bleeding, decreased uterine bleeding, increased scheduled uterine bleeding), abdominal/pelvic pain, amenorrhea, headache/migraine, genital discharge, vulvovaginitis

Serious Ectopic pregnancy, intrauterine pregnancy, Group A Streptococcal sepsis, pelvic inflammatory disease, uterine perforation, expulsion, ovarian cysts

Postmarketing Arterial thrombotic and venous thromboembolic events (pulmonary embolism, deep vein thrombosis, stroke), device breakage, hypersensitivity (rash, urticaria, angioedema), increased blood pressure

Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased

Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions

Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration

Pharmacology

Levonorgestrel-releasing intrauterine system; works locally by thickening cervical mucus to prevent sperm passage, inhibiting sperm capacitation or survival, and altering the endometrium; ovulation is inhibited in some but not all users.

GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Mirena